

Obstetrics & Gynecology Science

Hyeong In Ha, et al. The incidence and survival of gynecologic cancer in Korea in 1999-2017

Supplementary Table 3. Distribution according to site and SEER stage, 2006-2017

	Localized	Regional	Distant	Unknown	Total
Cervix	24,903 (100)	12,001 (100)	3,514 (100)	4,723 (100)	45,141 (100)
Squamous cell carcinoma	19,028 (76.4)	9,511 (79.3)	2,385 (67.9)	2,960 (62.7)	33,884 (75.1)
Others	5,875 (23.6)	2,490 (20.7)	1,129 (32.1)	1,763 (37.3)	11,257 (24.9)
Endometrium	15,838 (100)	3,955 (100)	1,527 (100)	1,465 (100)	22,785 (100)
Endometrioid	12,397 (78.3)	2,655 (67.1)	630 (41.3)	749 (51.1)	16,431 (72.1)
Others	3,441 (21.7)	1,300 (32.9)	897 (58.7)	716 (48.9)	6,354 (27.9)
POFT	5,890 (100)	4,350 (100)	11,314 (100)	1,388 (100)	22,942 (100)
Serous	1,510 (25.6)	2,377 (54.6)	7,696 (68.0)	582 (41.9)	12,165 (53.0)
Mucinous	1,749 (29.7)	417 (9.6)	601 (5.3)	211 (15.2)	2,978 (13.0)
Endometrioid	880 (14.9)	594 (13.7)	469 (4.1)	89 (6.4)	2,032 (8.9)
Clear cell	1,135 (19.3)	518 (11.9)	474 (4.2)	87 (6.3)	2,214 (9.7)
Other carcinoma	616 (10.5)	444 (10.2)	2,074 (18.3)	419 (30.2)	3,553 (15.5)

Values are presented as number (%).

SEER, Surveillance, Epidemiology, and End Results; POFT, primary peritoneal, ovarian epithelial, fallopian tube.